Insulet [PODD] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Insulet Corporation

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Insulet Corporation wins in 6 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Insulet Corporation Abbott Laboratories Better
P/E Ratio (TTM) 55.27 25.97 Abbott Laboratories
Price-to-Book Ratio 8.93 3.09 Abbott Laboratories
Debt-to-Equity Ratio 66.18 26.79 Abbott Laboratories
PEG Ratio 23.80 -1.41 Insulet Corporation
EV/EBITDA 24.51 13.74 Abbott Laboratories
Profit Margin (TTM) 9.12% 13.90% Abbott Laboratories
Operating Margin (TTM) 18.67% 16.50% Insulet Corporation
EBITDA Margin (TTM) 18.67% 16.50% Insulet Corporation
Return on Equity 18.12% 12.36% Insulet Corporation
Return on Assets (TTM) 9.43% 7.52% Insulet Corporation
Free Cash Flow (TTM) $349.90M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -50.86% -34.98% Abbott Laboratories
Price-to-Sales Ratio (TTM) 5.00 3.57 Abbott Laboratories
Enterprise Value $13.83B $166.96B Abbott Laboratories
EV/Revenue Ratio 5.11 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 72.54% N/A N/A
Revenue per Share (TTM) $39 $26 Insulet Corporation
Earnings per Share (Diluted) $3.48 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.47 0.78 Abbott Laboratories
Short % of Float 4.97% 1.53% Abbott Laboratories

Insulet Corporation vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

PODD
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Insulet Corporation-1.04%-2.22%0.46%-34.06%-49.18%-47.64%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Insulet Corporation-50.86%-47.38%-46.64%417.99%674.84%886.17%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Insulet Corporation vs Abbott Laboratories

MetricPODDABT
Market Information
Market Cap i$13.53B$160.70B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i743,37113,495,583
90 Day Avg. Volume i897,96012,934,461
Last Close$148.14$88.67
52 Week Range$140.63 - $354.88$81.97 - $139.06
% from 52W High-58.26%-36.24%
All-Time High$354.88 (Nov 20, 2025)$142.60 (Dec 27, 2021)
% from All-Time High-58.26%-37.82%
Growth Metrics
Quarterly Revenue Growth0.31%0.08%
Quarterly Earnings Growth0.01%-0.19%
Financial Health
Profit Margin (TTM) i0.09%0.14%
Operating Margin (TTM) i0.19%0.17%
Return on Equity (TTM) i0.18%0.12%
Debt to Equity (MRQ) i66.1826.79
Cash & Liquidity
Book Value per Share (MRQ)$21.53$30.02
Cash per Share (MRQ)$10.17$5.14
Operating Cash Flow (TTM) i$569.30M$10.80B
Levered Free Cash Flow (TTM) i$154.90M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Insulet Corporation vs Abbott Laboratories

MetricPODD (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i55.2725.97
Forward P/E i23.8015.29
PEG Ratio i23.80-1.41
Price to Sales (TTM) i5.003.57
Price to Book (MRQ) i8.933.09
Market Capitalization
Market Capitalization i$13.53B$160.70B
Enterprise Value i$13.83B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i5.113.70
Enterprise to EBITDA i24.5113.74
Risk & Other Metrics
Beta i1.470.78
Book Value per Share (MRQ) i$21.53$30.02

Financial Statements Comparison: Insulet Corporation vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPODD (2025)ABT (2025)
Revenue/Sales i2.71B44.33B
Cost of Goods Sold i768.20M19.32B
COGS % of Revenue i28.4%43.6%
Gross Profit i1.94B25.01B
Gross Margin i71.6%56.4%
Research & Development i301.10M2.94B
Operating Income (EBIT) i473.80M8.05B
Operating Margin i17.5%18.2%
EBITDA i600.70M12.03B
EBITDA Margin i22.2%27.1%
Pre-Tax Income i339.50M8.47B
Pre-Tax Income % of Revenue i12.5%19.1%
Income Tax i92.40M1.94B
Income Tax % of Revenue i3.4%4.4%
Net Income (Profit) i247.10M6.52B
Profit Margin i9.1%14.7%

Balance Sheet & Liquidity Metrics

MetricPODD (2025)ABT (2025)
Cash & Equivalents i716.10M8.52B
Total Current Assets i1.91B26.00B
Total Current Assets % of Revenue i70.7%58.6%
Total Current Liabilities i680.10M16.50B
Total Current Liabilities % of Revenue i25.1%37.2%
Long-Term Debt i930.80M10.83B
Long-Term Debt % of Revenue i34.4%24.4%
Total Shareholders Equity i1.52B52.77B
Retained Earnings i287.40M49.78B
Retained Earnings % of Revenue i10.6%112.3%
Property, Plant & Equipment i017.57B

Cash Flow Statement Comparison

MetricPODD (2025)ABT (2025)
Operating Cash Flow i374.00M10.80B
Operating Cash Flow % of Revenue i13.8%24.4%
Capital Expenditures iN/A-2.17B
Free Cash Flow i349.90M7.40B
FCF Margin i12.9%16.7%
Debt Repayment i-1.21B-1.50B
Common Stock Repurchase i-59.60M-893.00M

Short Interest & Institutional Ownership Analysis

MetricPODDABT
Shares Short i3.05M23.83M
Short Ratio i3.131.93
Short % of Float i4.97%1.53%
Shares Outstanding i70.39M1.74B
Float Shares i70.10M1.73B
% Held by Insiders i0.31%0.54%
% Held by Institutions i105.62%82.23%
% Held by Public i-5.93%17.23%

Dividend Analysis & Yield Comparison: Insulet Corporation vs Abbott Laboratories

MetricPODDABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026